OMP-18R5 (Vantictumab) targets the FZD1, FZD2, FZD5, FZD7, and FZD8 frizzled protein receptors to block WNT signaling are being investigated in phase I clinical trials in breast, pancreatic, and non-small cell lung cancer. This evidence concerns the gene FZD1 and non-small cell lung carcinoma.